RAC1 and hepatocellular carcinoma: In the work entitled “A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter.” These carcinoma xenograft mice were originally planned to be treated with ZYZ384 for 30 days.